489 related articles for article (PubMed ID: 23523410)
1. Clinical development of Modified Vaccinia virus Ankara vaccines.
Gilbert SC
Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
[TBL] [Abstract][Full Text] [Related]
2. Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector.
Pavot V; Sebastian S; Turner AV; Matthews J; Gilbert SC
Methods Mol Biol; 2017; 1581():97-119. PubMed ID: 28374245
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
4. Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.
Volz A; Sutter G
Vaccine; 2013 Sep; 31(39):4235-40. PubMed ID: 23523402
[TBL] [Abstract][Full Text] [Related]
5. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
Volz A; Sutter G
Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
[TBL] [Abstract][Full Text] [Related]
6. Recombinant MVA vaccines: dispelling the myths.
Cottingham MG; Carroll MW
Vaccine; 2013 Sep; 31(39):4247-51. PubMed ID: 23523407
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Meseda CA; Atukorale V; Kuhn J; Schmeisser F; Weir JP
PLoS One; 2016; 11(2):e0149364. PubMed ID: 26895072
[TBL] [Abstract][Full Text] [Related]
8. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
9. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
Sutter G; Staib C
Curr Drug Targets Infect Disord; 2003 Sep; 3(3):263-71. PubMed ID: 14529359
[TBL] [Abstract][Full Text] [Related]
10. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
Perera LP; Waldmann TA; Mosca JD; Baldwin N; Berzofsky JA; Oh S
J Virol; 2007 Aug; 81(16):8774-83. PubMed ID: 17553867
[TBL] [Abstract][Full Text] [Related]
11. Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
Alharbi NK
Hum Vaccin Immunother; 2019; 15(1):203-209. PubMed ID: 30148692
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.
Grandpre LE; Duke-Cohan JS; Ewald BA; Devoy C; Barouch DH; Letvin NL; Reinherz EL; Baden LR; Dolin R; Seaman MS
Vaccine; 2009 Mar; 27(10):1549-56. PubMed ID: 19168105
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
[TBL] [Abstract][Full Text] [Related]
15. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
[TBL] [Abstract][Full Text] [Related]
16. Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers.
Yoshikawa T
Vaccine; 2021 Oct; 39(41):6174-6181. PubMed ID: 34521550
[TBL] [Abstract][Full Text] [Related]
17. [Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine].
Volz A; Fux R; Langenmayer MC; Sutter G
Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):464-72. PubMed ID: 26697713
[TBL] [Abstract][Full Text] [Related]
18. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
Greenberg RN; Overton ET; Haas DW; Frank I; Goldman M; von Krempelhuber A; Virgin G; Bädeker N; Vollmar J; Chaplin P
J Infect Dis; 2013 Mar; 207(5):749-58. PubMed ID: 23225902
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]